Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) PT at $23.00

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been given a consensus rating of “Buy” by the seven analysts that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $23.00.

Several analysts have recently commented on AURA shares. BTIG Research raised their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Scotiabank raised their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research report on Thursday.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $9.97 on Tuesday. The firm has a market cap of $494.61 million, a price-to-earnings ratio of -5.81 and a beta of 0.33. Aura Biosciences has a 52-week low of $6.63 and a 52-week high of $12.38. The firm has a 50 day moving average price of $9.75 and a two-hundred day moving average price of $8.50.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, equities research analysts predict that Aura Biosciences will post -1.7 EPS for the current fiscal year.

Insider Activity at Aura Biosciences

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the transaction, the chief technology officer now directly owns 121,132 shares in the company, valued at approximately $1,193,150.20. This trade represents a 5.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Julie B. Feder sold 25,131 shares of the firm’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the transaction, the chief financial officer now owns 134,276 shares in the company, valued at approximately $1,615,340.28. This trade represents a 15.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 67,259 shares of company stock valued at $780,699. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aura Biosciences

Hedge funds have recently made changes to their positions in the business. American Century Companies Inc. purchased a new position in shares of Aura Biosciences in the 2nd quarter worth about $119,000. American International Group Inc. lifted its holdings in Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares during the last quarter. Virtu Financial LLC purchased a new stake in Aura Biosciences during the first quarter valued at about $144,000. SG Americas Securities LLC purchased a new stake in Aura Biosciences during the third quarter valued at about $169,000. Finally, Rhumbline Advisers lifted its holdings in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.